Summary
We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185HER2 monoclonal antibody (MKC-454) in 18 patients with metastatic breast cancer refractory to chemotherapy. Three or six patients at each dose level received 1, 2, 4 and 8 mg kg–1 of MKC-454 as 90-min intravenous infusions. The first dose was followed in 3 weeks by nine weekly doses. Target trough serum concentration has been set at 10 μg ml–1 based on in vitro observations. The mean value of minimum trough serum concentrations at each dose level were 3.58 ± 0.63, 6.53 ± 5.26, 40.2 ± 7.12 and 87.9 ± 23.5 μg ml–1 respectively. At 2 mg kg–1, although minimum trough serum concentrations were lower than the target trough concentration with a wide range of variation, trough concentrations increased and exceeded the target concentration, as administrations were repeated weekly. Finally 2 mg kg–1 was considered to be sufficient to achieve the target trough concentration by the weekly dosing regimen. One patient receiving 1 mg kg–1 had grade 3 fever, one at the 1 mg kg–1 level had severe fatigue defined as grade 3, and one at 8 mg kg–1 had severe bone pain of grade 3. No antibodies against MKC-454 were detected in any patients. Objective tumour responses were observed in two patients; one receiving 4 mg kg–1 had a partial response in lung metastases and the other receiving 8 mg kg–1 had a complete response in soft tissue metastases. These results indicate that MKC-454 is well tolerated and effective in patients with refractory metastatic breast cancers overexpressing the HER2 proto-oncogene. Further evaluation of this agent with 2–4 mg kg–1 weekly intravenous infusion is warranted.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baselga, J, Tripathy, D, Mendelsohn, J, Baughman, S, Benz, CC, Danits, L, Sklarin, NT, Seidman, AD, Hudis, CA, Moore, J, Rosen, PP, Twaddell, T, Henderson, IC & Norton, L (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744.
Carter, P, Presta, L, Gorman, CM, Ridgway, JBB, Henner, D, Wong, WLT, Rowland, AM, Kotts, C, Carver, ME & Shepard, HM (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289.
Coussens, L, Yang-Feng, TL, Liao, Y-C, Chen, E, Gray, A, McGrath, J, Seeburg, PH, Liebermann, TW, Schlessinger, J, Franke, U, Levison, A & Ullrich, A (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139.
De Potter, CR, Van Daele, S, Van De Vijver, MJ, Pauwels, C, Maertens, G, De Boever, J, Vandekerckhove, D & Roels, H (1989). The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 15: 315–326.
Drebin, JA, Link, VC, Stern, DF, Weinberg, RA & Green, MI (1985). Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 695–706.
Eger, RR, Covell, DG, Carrasquillo, JA, Abrams, PG, Foon, KA, Reynolds, JC, Schroff, RW, Morgan, AC, Larson, SM & Weinstein, JN (1987). Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res 47: 3328–3336.
Hancock, MC, Langton, BC, Chan, T, Toy, P, Monahan, JJ, Mischak, RP & Shawver, LK (1991). A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumour cell lines. Cancer Res 51: 4575–4580.
Harwerth, I-M, Wels, W, Marte, BM & Hynes, NE (1992). Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267: 15160–15167.
Hudziak, RM, Lewis, GD, Winget, M, Fendly, BM, Shepard, M & Ullrich, A (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172.
Kasprzyk, PG, Song, SU, Di Fiore, PP & King, CR (1992). Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52: 2771–2776.
King, CR, Kraus, MH & Aronson, SA (1985). Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976.
Koizumi, K, DeNardo, GL, DeNardo, SJ, Hays, MT, Hines, HH, Scheibe, PO, Peng, J, Macey, DJ, Tonami, N & Hisada, K (1986). Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. J Nucl Med 27: 1243–1254.
Pegram, MD, Lipton, A, Hayes, DF, Weber, BL, Baselga, JM, Tripathy, D, Baly, D, Baughman, SA, Twaddell, T, Glaspy, JA & Slamon, DJ (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659–2671.
Press, MF, Cerdon-Cardo, C & Slamon, DJ (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953–962.
Schroff, RW, Foon, KA, Beatty, SM, Oldham, RK & Morgan, Jr AC (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45: 879–885.
Scott, GK, Robles, R, Park, JW, Montgomery, PA, Daniel, J, Holmes, WE, Lee, J, Keller, GA, Li, WL, Fendly, BM, Wood, WI, Shepard, HM & Benz, CC (1993). A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13: 2247–2257.
Shawler, DL, Bartholomew, RM, Smith, LM & Dillman, RO (1985). Human immune response to multiple injection of murine monoclonal IgG. J Immunol 135: 1530–1535.
Slamon, DJ, Godolphin, W, Jones, LA, Holt, JA, Wong, SG, Keith, DE, Levin, WJ, Stuart, SG, Udove, J, Ullrich, A & Press, MF (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
Stankovski, I, Hurwitz, E, Leitner, O, Ullrich, A, Yarden, Y & Sela, M (1991). Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc Natl Acad Sci USA 88: 8691–8695.
Tagliabue, E, Centis, F, Campiglio, M, Mastroianni, A, Martignone, S, Pellegrini, R, Casalini, P, Lanzi, C, Menard, S & Colnaghi, MI (1991). Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 47: 933–937.
Tobinai, K, Kohno, A, Shimada, Y, Watanabe, T, Tamura, T, Takeyama, K, Narabayashi, M, Fukutomi, T, Kondo, H, Shimoyama, M & Suemasu, K (1993). Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23: 250–257.
Tokuda, Y, Ohnishi, Y, Shimamura, K, Iwasawa, M, Yoshimura, M, Ueyama, Y, Tamaoki, N, Tajima, T & Mitomi, T (1996). In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73: 1362–1365.
Yamamoto, T, Ikawa, S, Akiyama, T, Semba, K, Nomura, N, Miyajima, N, Saito, T & Toyoshima, K (1986). Similarity of protein encoded by human c-erbB-2 gene to epidermal growth factor receptor. Nature 319: 230–234.
Yarden, Y & Ullrich, A (1988). Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443–478.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Tokuda, Y., Watanabe, T., Omuro, Y. et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81, 1419–1425 (1999). https://doi.org/10.1038/sj.bjc.6690343
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690343
Keywords
This article is cited by
-
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
EJNMMI Research (2021)
-
Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies
Current Pharmacology Reports (2018)
-
Welke assays kunnen de arts in de kliniek helpen
Bijblijven (2018)
-
A novel way to manage trastuzumab cardiotoxicity
Cancer Chemotherapy and Pharmacology (2018)
-
Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability
Journal of Pharmacokinetics and Pharmacodynamics (2017)